Skip to content
Company Analysis

Thermo Fisher Scientific Inc TMO

A comprehensive view of key metrics, scores, and financial health for Thermo Fisher Scientific Inc

Overview of Thermo Fisher Scientific Inc.

TMO NYQ
Healthcare Diagnostics & Research Large Cap
Thermo Fisher Scientific Inc. (TMO), is a Large Cap company, in the Diagnostics & Research industry, last closed at $464.37, about 43.9% overvalued vs fair value, -10.6% 1Y return, placing in the top 10% of its sector.
$464.37
-2.42%
As of March 13, 2026
Previous close • Vol 90d: 24.7%
52-Week Range
Market Cap
$186.47B
Enterprise Value
$216.01B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Thermo Fisher Scientific Inc.

Top Beats
No strong beats yet

Quick Facts

Website https://www.thermofisher.com
HQ Waltham, MA
Employees 125,000
Fiscal year Dec 31

Next Events

Dividend Apr 15
Earnings Apr 22 Estimated

Fair Value Snapshot

Bear Base Bull
$234
$260
$290
Current: $464.37 -44% vs base

Engine Room Money Flow™

Large Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$44.6B
3.9%%
Gross Profit
$16.8B
-5.2%%
Operating Income
$8.1B
5.1%%
Net Income
$6.7B
6.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
107.9%
Excellent

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$6.0B
83.1% of FCF

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
1
Active Leaks
0/1
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Thermo Fisher Scientific Inc's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
69
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
65
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing TMO's balance between Growth (22.6%), Profitability (42.1%), and Safety (35.3%). Growth 23% Safety 35% Profitability 42%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

41th percentile vs peers
41
Key Signals
Rev Growth YoY 3.9% 37p EPS CAGR 3Y 0.3% 58p TSR 11.7% 72p Revenue CAGR 3Y -0.3% 28p EPS Growth YoY 7.8% 35p
Strengths
  • Superior capital returns - 3 return metrics above peer median
  • Operating Margin in top 20% of peers (18.2%, 82th percentile)
  • Roic in top 20% of peers (8.7%, 81th percentile)
Risks

No significant risks identified for this axis.

Profitability

77th percentile vs peers
77
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

64th percentile vs peers
65
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Thermo Fisher Scientific Inc.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$260.44
- - -
-43.9% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info